NASDAQ:HOLX - Hologic Stock Price, Price Target & More

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Hologic, Inc. (NASDAQ:HOLX) issued its quarterly earnings results on Wednesday, May, 2nd. The medical equipment provider reported $0.53 EPS for the quarter, meeting the Zacks' consensus estimate of $0.53. The medical equipment provider had revenue of $789.30 million for the quarter, compared to analysts' expectations of $781.23 million. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The business's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.50 earnings per share. View Hologic's Earnings History.

Hologic updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share guidance of $2.22-2.27 for the period, compared to the Thomson Reuters consensus estimate of $2.26. The company issued revenue guidance of $3.18-3.21 billion, compared to the consensus revenue estimate of $3.25 billion.Hologic also updated its Q3 guidance to $0.55-0.57 EPS.

14 brokers have issued twelve-month price objectives for Hologic's stock. Their forecasts range from $39.00 to $52.00. On average, they anticipate Hologic's share price to reach $45.00 in the next twelve months. This suggests a possible upside of 8.4% from the stock's current price. View Analyst Ratings for Hologic.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Hologic saw a decline in short interest in June. As of June 15th, there was short interest totalling 8,793,455 shares, a decline of 19.1% from the May 31st total of 10,875,616 shares. Based on an average daily volume of 2,507,848 shares, the short-interest ratio is presently 3.5 days. Currently, 3.2% of the shares of the company are short sold. View Hologic's Current Options Chain.

Some companies that are related to Hologic include Express Scripts (ESRX), Illumina (ILMN), Humana (HUM), FRESENIUS SE &/S (FSNUY), Zoetis (ZTS), BEXIMCO PHARMAC/S GDR REGS (BXP), Baxter International (BAX), Regeneron Pharmaceuticals (REGN), HCA Healthcare (HCA), Takeda Pharmaceutical (TKPYY), ESSILOR Intl S/S (ESLOY), ASTELLAS PHARMA/ADR (ALPMY), Edwards Lifesciences (EW), Fresenius Medical Care AG & Co. (FMS) and Alexion Pharmaceuticals (ALXN).

Media coverage about HOLX stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Hologic earned a news impact score of 0.11 on Accern's scale. They also assigned news coverage about the medical equipment provider an impact score of 46.59 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Hologic's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include American Capital Management Inc. (0.43%), Gateway Investment Advisers LLC (0.14%), Bank of Montreal Can (0.10%), Retirement Systems of Alabama (0.05%), Thompson Investment Management Inc. (0.03%) and Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%). Company insiders that own Hologic stock include Allison P Bebo, Charles J Dockendorff, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Namal Nawana, Nancy Leaming, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic.

HOLX stock was sold by a variety of institutional investors in the last quarter, including Central Bank & Trust Co., Retirement Systems of Alabama, Webster Bank N. A. and American Capital Management Inc.. Company insiders that have sold Hologic company stock in the last year include Allison P Bebo, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy and Peter J Valenti III. View Insider Buying and Selling for Hologic.

HOLX stock was purchased by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, Bank of Montreal Can, DnB Asset Management AS, Curbstone Financial Management Corp, Ledyard National Bank, NN Investment Partners Holdings N.V., State of Alaska Department of Revenue and IFM Investors Pty Ltd. Company insiders that have bought Hologic stock in the last two years include Charles J Dockendorff and Namal Nawana. View Insider Buying and Selling for Hologic.

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HOLX stock can currently be purchased for approximately $41.50.

Hologic has a market capitalization of $11.47 billion and generates $3.06 billion in revenue each year. The medical equipment provider earns $755.50 million in net income (profit) each year or $2.03 on an earnings per share basis. Hologic employs 6,233 workers across the globe.

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]